India’s pharmaceutical market is poised for explosive growth, with projections placing its value at US$130 billion by 2030 and an ambitious US$450 billion by 2047. This massive growth trajectory was highlighted ahead of a forthcoming three-day pharma-industry expo scheduled to begin on November 25, 2025. The projections underscore India’s strategic ambition to solidify its position as a dominant global pharma hub, moving beyond its historical role as the “Pharmacy of the World” for generic drugs.
The growth is being driven by several key factors. Domestically, the expansion of healthcare access through major government schemes like Ayushman Bharat, rising disposable incomes, and the increasing burden of chronic diseases are creating robust demand. Internationally, the focus is shifting toward high-value segments including complex generics, biosimilars, and innovation in Active Pharmaceutical Ingredients (APIs) to reduce import dependence on China.
India’s pharmaceutical industry, which currently ranks third globally by volume and 14th by value, is leveraging its established manufacturing base, skilled scientific workforce, and cost-competitive structure to achieve these targets. The government is supporting this through production-linked incentive (PLI) schemes for domestic manufacturing of critical drugs and medical devices, ensuring the sector remains a key pillar of the national economy.
